Antigen-Targeting Inserted Nanomicelles Guide Pre-Existing Immunity to Kill Head and Neck Cancer

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Virology

Background:

• Identifying specific and uniform tumor targets for cancer therapy remains a significant challenge, especially in heterogeneous tumors.
• The potential of pre-existing antiviral immunity in cancer treatment is often limited by the lack of corresponding tumor-associated antigens.

Purpose of the Study:

• To develop a novel nanomicelle platform for antigen-targeted cancer therapy.
• To leverage pre-existing immunity for tumor cell lysis by engineering nanomicelles to present viral antigens on tumor tissues.

Main Methods:

• Development of preS1 (hepatitis B virus antigen)-pHLIP nanomicelles designed for tumor targeting and antigen release.
• Evaluation of nanomicelle efficacy in animal models of head and neck cancers (squamous cell carcinoma, anaplastic thyroid cancer).
• Assessment of immune responses, including B cell and T cell activation within the tumor microenvironment.

Main Results:

• PreS1-pHLIP nanomicelles effectively inhibited tumor growth, recurrence, and metastasis in pre-immunized animal models.
• Therapeutic effects correlated with increased proportions of preS1-specific B cells and activated tumor-specific T cells.
• The nanomicelles successfully labeled tumor tissue, facilitating lysis via the pre-existing immune response.

Conclusions:

• Engineered nanomicelles can effectively disguise tumor cells as viruses, enabling tumor destruction through pre-existing antiviral immunity.
• This strategy offers a novel therapeutic approach for cancers with challenging or ambiguous target profiles.
• The platform demonstrates potential for enhancing cancer treatment by utilizing innate immune memory.